Direct Oral Anticoagulants in Gastrointestinal Malignancies: is the Convenience Worth the Risk?

Overview

Journal J Gastrointest Oncol

Date 2019 Aug 9

PMID 31392062

Citations 6

Authors

Namisha Thapa

Joseph Shatzel

Thomas G DeLoughery

Sven R Olson

Affiliations

Soon will be listed here.

Citing Articles

Low Molecular Weight Heparin Treatment Patterns and Outcomes in Cancer Patients with Acute Venous Thromboembolism: A Nationwide Cohort Study in France.

Bertoletti L, Gusto G, Quignot N, Khachatryan A, Chaves J, Moniot A Cancers (Basel). 2023; 15(11).

PMID: 37296971 PMC: 10251904. DOI: 10.3390/cancers15113011.

Management of Gastrointestinal Bleeding and Resumption of Oral Anticoagulant Therapy in Patients with Atrial Fibrillation: A Multidisciplinary Discussion.

Martin A, Benamouzig R, Gouin-Thibault I, Schmidt J Am J Cardiovasc Drugs. 2023; 23(4):407-418.

PMID: 37145342 PMC: 10329066. DOI: 10.1007/s40256-023-00582-9.

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism.

Li M, Li J, Wang X, Hui X, Wang Q, Xie S Cochrane Database Syst Rev. 2023; 4:CD010957.

PMID: 37057837 PMC: 10103165. DOI: 10.1002/14651858.CD010957.pub3.

Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants.

Benamouzig R, Guenoun M, Deutsch D, Fauchier L Cardiovasc Drugs Ther. 2021; 36(5):973-989.

PMID: 34143317 DOI: 10.1007/s10557-021-07211-0.

The efficacy and safety of DOACs versus LMWH for cancer-associated thrombosis: A systematic review and meta-analysis.

Tao D, Olson S, DeLoughery T, Shatzel J Eur J Haematol. 2020; 105(3):360-362.

PMID: 32441350 PMC: 8086370. DOI: 10.1111/ejh.13453.

References

Lee A, Levine M, Baker R, Bowden C, Kakkar A, Prins M . Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2):146-53. DOI: 10.1056/NEJMoa025313. View

Vaduganathan M, Bhatt D . Gastrointestinal Bleeding With Oral Anticoagulation: Understanding the Scope of the Problem. Clin Gastroenterol Hepatol. 2017; 15(5):691-693. DOI: 10.1016/j.cgh.2016.12.033. View

Raskob G, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D . Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2017; 378(7):615-624. DOI: 10.1056/NEJMoa1711948. View

Li A, Garcia D, Lyman G, Carrier M . Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res. 2018; 173:158-163. PMC: 6119655. DOI: 10.1016/j.thromres.2018.02.144. View

Young A, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C . Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018; 36(20):2017-2023. DOI: 10.1200/JCO.2018.78.8034. View